Please use this identifier to cite or link to this item:
https://doi.org/10.1186/s13045-015-0163-z
Title: | Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: A clinicopathologic analysis of 61 patients | Authors: | Loghavi, S Alayed, K Aladily, T.N Zuo, Z Ng, S.-B Tang, G Hu, S Yin, C.C Miranda, R.N Medeiros, L.J Khoury, J.D |
Keywords: | cyclophosphamide dexamethasone doxorubicin etoposide prednisone vincristine antineoplastic agent abdominal pain adult age distribution aged Article cancer chemotherapy cancer prognosis cancer staging cancer survival carcinogenesis clinical evaluation cohort analysis colorimetry controlled study correlational study cytogenetics diarrhea epistaxis Epstein Barr virus Epstein Barr virus infection event free survival female fluorescence in situ hybridization follow up gastrointestinal symptom gene overexpression gene rearrangement health impact assessment histopathology human Human immunodeficiency virus infection human tissue immunocompromised patient immunophenotyping major clinical study male nose ulcer oncogene myc outcome assessment overall survival plasmablastic lymphoma rectum hemorrhage rhinorrhea sinusitis very elderly virus detection age cancer staging complication Epstein Barr virus infection genetics middle aged pathology plasmablastic lymphoma treatment outcome young adult Adult Age Factors Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols Cohort Studies Epstein-Barr Virus Infections Female Humans Male Middle Aged Neoplasm Staging Plasmablastic Lymphoma Treatment Outcome Young Adult |
Issue Date: | 2015 | Citation: | Loghavi, S, Alayed, K, Aladily, T.N, Zuo, Z, Ng, S.-B, Tang, G, Hu, S, Yin, C.C, Miranda, R.N, Medeiros, L.J, Khoury, J.D (2015). Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: A clinicopathologic analysis of 61 patients. Journal of Hematology and Oncology 8 (1) : 65. ScholarBank@NUS Repository. https://doi.org/10.1186/s13045-015-0163-z | Rights: | Attribution 4.0 International | Abstract: | Background: Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic features have been largely derived from cases reports and small series with limited outcome analyses. Patients and methods: The demographic, clinicopathologic features, and clinical outcomes of a cohort of 61 patients with PBL were reviewed and analyzed. Results: Patients had a median age of 49 years (range 21-83 years) and most (49/61; 80 %) were men. Human immunodeficiency virus (HIV) status was available for 50 patients: 20 were HIV-positive and 30 HIV-negative. Twenty-three patients were immunocompetent. Abdominal/gastrointestinal complaints were the most common presenting symptoms, reported in 14 of 47 (30 %) of patients. At presentation, 24 of 43 (56 %) patients had stage III or IV disease. Epstein-Barr virus (EBV) was detected in 40 of 57 (70 %) cases. MYC rearrangement was identified in 10/15 (67 %) cases assessed, and MYC overexpression was seen in all cases assessed regardless of MYC rearrangement status. HIV-positive patients were significantly younger than those who were HIV-negative (median 42 vs. 58 years; p∈=∈0.006). HIV-positive patients were also significantly more likely to have EBV-positive disease compared with HIV-negative patients (19/19, 100 % vs. 15/29, 52 %; p∈=∈0.002). Patients who received CHOP chemotherapy tended to have better overall survival (OS) compared with those who received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) (p∈=∈0.078). HIV status had no impact on OS. Patients with EBV-positive PBL had a better event-free survival (EFS) (p∈=∈0.047) but not OS (p∈=∈0.306). Notably, OS was adversely impacted by age ge;50 years (p∈=∈0.013), stage III or IV disease (p∈=∈<0.001), and lymph node involvement (p∈=∈0.008). Conclusions: The most significant prognostic parameters in patients with PBL are age, stage, and, to a lesser extent, EBV status. In this study, two-thirds of PBL cases assessed were associated with MYC rearrangement and all showed MYC overexpression. © 2015 Loghavi et al. | Source Title: | Journal of Hematology and Oncology | URI: | https://scholarbank.nus.edu.sg/handle/10635/180909 | ISSN: | 17568722 | DOI: | 10.1186/s13045-015-0163-z | Rights: | Attribution 4.0 International |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1186_s13045-015-0163-z.pdf | 2.03 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License